Activation of AMP-activated protein kinase in cerebella of Atm-/- mice is attributable to accumulation of reactive oxygen species

Biochemical and Biophysical Research Communications

Volumn 418, Issue 2, 2012, Pages 267-272

  Kuang, Xianghong ^a   Yan, Mingshan ^a   Ajmo, Joanne M ^b   Scofield, Virginia L ^c   Stoica, George ^d   Wong, Paul K Y ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b Bach Pharma Inc   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d TEXAS A AND M UNIVERSITY   (United States)

Author keywords

AMPK; Ataxia telangiectasia; ATM; Cerebellum; Reactive oxygen species

Indexed keywords

ANTIOXIDANT; ATM PROTEIN; HYDROGEN PEROXIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MALONALDEHYDE; MONOSODIUM LUMINOL; PHOSPHORYLATED AMP ACTIVATED PROTEIN KINASE ALPHA; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CEREBELLUM; CONTROLLED STUDY; MOTONEURON; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; UPREGULATION;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTIOXIDANTS; ATAXIA TELANGIECTASIA; CELL CYCLE PROTEINS; CEREBELLUM; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; HEREDODEGENERATIVE DISORDERS, NERVOUS SYSTEM; LUMINOL; MICE; MICE, MUTANT STRAINS; MUTATION; OXIDATIVE STRESS; PHTHALAZINES; PROTEIN-SERINE-THREONINE KINASES; REACTIVE OXYGEN SPECIES; TUMOR SUPPRESSOR PROTEINS;

ANIMALIA; ATAXIA TELANGIECTASIA; EPICOCCUM; MUS;

EID: 84856673305     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.01.008     Document Type: Article

References (42)

1. Lavin M.F. Radiosensitivity and oxidative signalling in ataxia telangiectasia: an update. Radiother. Oncol. 1998, 47:113-123.
2. Wong P.K., Kim S., Kuang X., Lynn W. Oxidative stress-mediated neurodegeneration: a tale of two models. Neurodegeneration: Theory, Disorder and Treatment 2011, Nova Biomedical Science Publisher, Inc., pp. 1. A.S. McNeil (Ed.).
3. Barlow C., Hirotsune S., Paylor R., et al. Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell 1996, 86:159-171.
4. Barzilai A., Rotman G., Shiloh Y. ATM deficiency and oxidative stress: a new dimension of defective response to DNA damage. DNA Repair (Amst.) 2002, 1:3-25.
5. Barlow C., Dennery P.A., Shigenaga M.K., et al. Loss of the ataxia-telangiectasia gene product causes oxidative damage in target organs. Proc. Natl. Acad. Sci. USA 1999, 96:9915-9919.
6. Kim J., Wong P.K. Oxidative stress is linked to ERK1/2-p16 signaling-mediated growth defect in ATM-deficient astrocytes. J. Biol. Chem. 2009, 284:14396-14404.
7. Liu N., Stoica G., Yan M., et al. ATM deficiency induces oxidative stress and endoplasmic reticulum stress in astrocytes. Lab. Invest. 2005, 85:1471-1480.
8. Kim J., Wong P.K. Loss of ATM impairs proliferation of neural stem cells through oxidative stress-mediated p38 MAPK signaling. Stem cells 2009, 27:1987-1998.
9. Bright N.J., Thornton C., Carling D. The regulation and function of mammalian AMPK-related kinases. Acta. Physiol. (Oxf.) 2009, 196:15-26.
10. Viollet B., Andreelli F. AMP-activated protein kinase and metabolic control. Handb. Exp. Pharmacol. 2011, 203:303-330.
11. Williams K.W., Coppari R., Elmquist J.K. " AMPing up" our understanding of the hypothalamic control of energy balance. J. Clin. Invest. 2007, 117:2089-2092.
12. Poels J., Spasic M.R., Callaerts P., et al. Expanding roles for AMP-activated protein kinase in neuronal survival and autophagy. Bioassays 2009, 31:944-952.
13. Fehm H.L., Kern W., Peters A. The selfish brain: competition for energy resources. Prog. Brain. Res. 2006, 153:129-140.
14. Turnley A.M., Stapleton D., Mann R.J., et al. Cellular distribution and developmental expression of AMP-activated protein kinase isoforms in mouse central nervous system. J. Neurochem. 1999, 72:1707-1716.
15. Culmsee C., Monnig J., Kemp B.E., et al. AMP-activated protein kinase is highly expressed in neurons in the developing rat brain and promotes neuronal survival following glucose deprivation. J. Mol. Neurosci. 2001, 17:45-58.
16. Kwon K.J., Kim H.J., Shin C.Y., et al. Melatonin potentiates the neuroprotective properties of resveratrol against beta-amyloid-induced neurodegeneration by modulating AMP-activated protein kinase pathways. J. Clin. Neurol. 2010, 6:127-137.
17. McCullough L.D., Zeng Z., Li H., et al. Pharmacological inhibition of AMP-activated protein kinase provides neuroprotection in stroke. J. Biol. Chem. 2005, 280:20493-20502.
18. Kuramoto N., Wilkins M.E., Fairfax B.P., et al. Phospho-dependent functional modulation of GABA(B) receptors by the metabolic sensor AMP-dependent protein kinase. Neuron 2007, 53:233-247.
19. Yoon H., Oh Y.T., Lee J.Y., et al. Activation of AMP-activated protein kinase by kainic acid mediates brain-derived neurotrophic factor expression through a NF-kappaB dependent mechanism in C6 glioma cells. Biochem. Biophys. Res. Commun. 2008, 371:495-500.
20. Kim M.S., Park J.Y., Namkoong C., et al. Anti-obesity effects of alpha-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase. Nat. Med. 2004, 10:727-733.
21. Suzuki A., Kusakai G., Kishimoto A., et al. IGF-1 phosphorylates AMPK-alpha subunit in ATM-dependent and LKB1-independent manner. Biochem. Biophys. Res. Commun. 2004, 324:986-992.
22. Sun Y., Connors K.E., Yang D.Q. AICAR induces phosphorylation of AMPK in an ATM-dependent, LKB1-independent manner. Mol. Cell. Biochem. 2007, 306:239-245.
23. Kamsler A., Daily D., Hochman A., et al. Increased oxidative stress in ataxia telangiectasia evidenced by alterations in redox state of brains from Atm-deficient mice. Cancer Res. 2001, 61:1849-1854.
24. Emerling B.M., Weinberg F., Snyder C., et al. Hypoxic activation of AMPK is dependent on mitochondrial ROS but independent of an increase in AMP/ATP ratio. Free Radic. Biol. Med. 2009, 46:1386-1391.
25. Kuang X., Shen J., Wong P.K., et al. Deregulation of mTOR signaling is involved in thymic lymphoma development in Atm-/- mice. Biochem. Biophys. Res. Commun. 2009, 383:368-372.
26. Liao M.J., Yin C., Barlow C., et al. Atm is dispensable for p53 apoptosis and tumor suppression triggered by cell cycle dysfunction. Mol. Cell. Biol. 1999, 19:3095-3102.
27. Grinberg L., Fibach E., Amer J., et al. N-acetylcysteine amide, a novel cell-permeating thiol, restores cellular glutathione and protects human red blood cells from oxidative stress. Free Radic. Biol. Med. 2005, 38:136-145.
28. Jiang Y., Scofield V.L., Yan M., et al. Retrovirus-induced oxidative stress with neuroimmunodegeneration is suppressed by antioxidant treatment with a refined monosodium alpha-luminol (Galavit). J. Virol. 2006, 80:4557-4569.
29. Yan M., Zhu C., Liu N., et al. ATM controls c-Myc and DNA synthesis during postnatal thymocyte development through regulation of redox state. Free Radic. Biol. Med. 2006, 41:640-648.
30. Ito K., Hirao A., Arai F., et al. Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. Nature 2004, 431:997-1002.
31. Yan M., Qiang W., Liu N., et al. The ataxia-telangiectasia gene product may modulate DNA turnover and control cell fate by regulating cellular redox in lymphocytes. FASEB J. 2001, 15:1132-1138.
32. Ambrose M., Goldstine J.V., Gatti R.A. Intrinsic mitochondrial dysfunction in ATM-deficient lymphoblastoid cells. Hum. Mol. Genet. 2007, 16:2154-2164.
33. Cheema A.K., Timofeeva O., Varghese R., et al. Integrated analysis of ATM mediated gene and protein expression impacting cellular metabolism. J. Proteome Res. 2011, 10:2651-2657.
34. Salminen A., Kaarniranta K., Haapasalo A., et al. AMP-activated protein kinase: a potential player in Alzheimer's disease. J Neurochem. 2011, 118:460-474.
35. Axelsen P.H., Komatsu H., Murray I.V. Oxidative stress and cell membranes in the pathogenesis of Alzheimer's disease. Physiology (Bethesda) 2011, 26:54-69.
36. Pac-Soo C., Lloyd D.G., Vizcaychipi M.P., et al. Statins: the role in the treatment and prevention of Alzheimer's neurodegeneration. J. Alzheimers Dis. 2011, 27:1-10.
37. Galano A., Tan D.X., Reiter R.J. Melatonin as a natural ally against oxidative stress: a physicochemical examination. J. Pineal. Res. 2011, 51:1-16.
38. Bonnefont-Rousselot D., Collin F. Melatonin: action as antioxidant and potential applications in human disease and aging. Toxicology 2010, 278:55-67.
39. Pintea A., Rugina D., Pop R., et al. Antioxidant effect of trans-resveratrol in cultured human retinal pigment epithelial cells. J. Ocul. Pharmacol. Ther. 2011, 27:315-321.
40. Jones R.G., Plas D.R., Kubek S., et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol. Cell 2005, 18:283-293.
41. Reddy P.V., Lungu G., Kuang X., et al. Neuroprotective effects of the drug GVT (monosodium luminol) are mediated by the stabilization of Nrf2 in astrocytes. Neurochem. Int. 2010, 56:780-788.
42. Qiang W., Cahill J.M., Liu J., et al. Activation of transcription factor Nrf-2 and its downstream targets in response to moloney murine leukemia virus ts1-induced thiol depletion and oxidative stress in astrocytes. J. Virol. 2004, 78:11926-11938.